globenewswire

Vallourec Geothermal Deep Dive

La Hulpe, Belgium - 15 June 2026, 7:00 a.m. CET – INSIDE INFORMATION - Banqup Group SA (Euronext Brussels: BANQ) (“Banqup” or the “Company”) today announces that, following an extensive review, the Board has approved a strategic simplification plan to reorganize the Group into distinct, autonomous business units to enhance operational focus and transparency. Lazard is mandated to explore all strategic options, including the sale of individual business units or the Group as a whole in order to maximize stakeholder value.

Please find attached the 2026 version of the Salmon Farming Industry Handbook. The handbook is also available on our website www.mowi.com.

THIS NEWS RELEASE IS NOT FOR DISSEMINATION OR DISTRIBUTION IN THE UNITED STATES OF AMERICA TO UNITED STATES NEWSWIRE SERVICES OR UNITED STATES PERSONS

MONACO city, Monaco , June 14, 2026 (GLOBE NEWSWIRE) -- Crypto news today is turning toward AlphaPepe after the project confirmed that Stage 17 of its presale has sold out and Stage 18 is now live. The presale has raised over $1.55 million, the current token price is $0.01896, and holder growth has climbed above 9,500 as AlphaSwap Early Access, live AI features, and a pending first CEX partnership reveal strengthen the project’s pre-listing profile.

NEW YORK, June 14, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of POET Technologies Inc. (NASDAQ: POET) between April 1, 2026 and 08:57 AM ET on April 27, 2026, inclusive (the “Class Period”), of the important June 29, 2026 lead plaintiff deadline in the securities class action first filed by the Firm.

NEW YORK, June 14, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of Class A or Class C common stock of Zillow Group, Inc. (NASDAQ: ZG) (NASDAQ: Z) between February 11, 2025 and May 7, 2026, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 10, 2026 in the securities class action first filed by the Firm.

NEW YORK, June 14, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of The Ensign Group, Inc. (NASDAQ: ENSG) resulting from allegations that Ensign may have issued materially misleading business information to the investing public.

ROCKVILLE, Md. and SUZHOU, China, June 14, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel therapies to address unmet medical needs in cancer, announced today that seventeen clinical updates from its core assets were presented at the 31^st Congress of the European Hematology Association (EHA2026), including eight poster presentations. The presentations featured data from ongoing clinical studies of olverembatinib (HQP1351), the first third-generation BCR-ABL1 inhibitor approved in China, and lisaftoclax (APG-2575), the first approved China-developed Bcl-2 selective inhibitor. The EHA2026 Congress convened in Stockholm, Sweden, from June 11 to 14, 2026.

NEW YORK, June 14, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of BitGo Holdings, Inc. (NYSE: BTGO): (i) Class A common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the “Offering Documents”) issued in connection with BitGo's January 22, 2026 initial public offering ("IPO"); and/or (ii) securities between January 22, 2026 and May 13, 2026, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 7, 2026.

Data show investigational atumelnant drove sustained androgen reductions while enabling lowering of glucocorticoid supplementation to physiologically normal levels in adults with classic CAH